Prostate Cancer Diagnosis: A Comprehensive Guide

Prostate cancer diagnosis is a critical step in managing this prevalent disease. If you’re navigating concerns about prostate cancer, understanding the diagnostic journey is essential. This detailed guide, based on insights from Mayo Clinic experts like urologist Dr. Mitchell Humphreys, will walk you through each stage of diagnosis, from initial screenings to advanced tests, ensuring you are well-informed and prepared.

Prostate cancer diagnosis typically commences with a physical examination and a blood test, often initiated as part of routine prostate cancer screening or when symptoms arise. If these preliminary tests indicate potential concerns, further imaging tests are employed to visualize the prostate gland for signs of malignancy. Ultimately, a prostate cell sample, obtained through a biopsy, is necessary to definitively confirm or rule out prostate cancer.

Prostate Cancer Screening: Early Detection Strategies

Prostate cancer screening is a proactive approach to detect prostate cancer in individuals who exhibit no symptoms. The primary screening tools include the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE).

Generally, discussions about prostate cancer screening should begin around age 50. This conversation between you and your healthcare provider will help determine if screening is appropriate for you, considering your individual risk factors and preferences. It’s advisable to initiate these discussions earlier, particularly if you are of Black ethnicity, have a family history of prostate cancer, or possess other elevated risk factors.

Digital Rectal Exam (DRE)

Digital Rectal Exam (DRE)

Alt text: Doctor performing a Digital Rectal Exam (DRE) to check prostate health, early diagnosis for prostate cancer.

The digital rectal exam is a manual examination of the prostate gland. During a DRE, a healthcare professional gently inserts a gloved and lubricated finger into the rectum. This allows them to physically assess the prostate gland, which is located adjacent to the rectum. The healthcare provider is evaluating the prostate’s texture, shape, and size for any irregularities that might suggest a prostate condition, including cancer.

A DRE is a quick and relatively simple procedure often included as part of routine prostate cancer screening. It may also be recommended if you are experiencing symptoms that suggest a prostate issue. While a DRE can provide valuable initial information, it is often used in conjunction with other tests, such as the PSA test, for a more comprehensive assessment.

Prostate-Specific Antigen (PSA) Test

The prostate-specific antigen (PSA) test is a blood test that quantifies the level of PSA in your bloodstream. PSA is a protein produced by prostate cells, and a small amount normally circulates in the blood. The PSA test measures this circulating PSA level in a blood sample.

Elevated PSA levels can be indicative of prostate cancer, but it’s crucial to understand that high PSA levels are not exclusive to cancer. Other conditions, such as prostate infections (prostatitis) and benign prostatic hyperplasia (BPH), or prostate enlargement, can also elevate PSA levels. If an initial PSA test reveals an elevated level, it is typically repeated to confirm the finding. Your healthcare provider may recommend a repeat test within a few weeks to monitor if the PSA level decreases. Persistent elevation of PSA may warrant further diagnostic investigations, such as imaging tests or a prostate biopsy, to determine the underlying cause and check for cancer.

The PSA test is widely utilized for prostate cancer screening and may also be employed when symptoms suggestive of prostate cancer are present. The PSA test results provide valuable clues that aid healthcare professionals in diagnosis and further management.

Prostate Ultrasound: Visualizing the Prostate

Prostate ultrasound is an imaging technique that employs sound waves to create visual representations of the prostate gland. This procedure is often recommended if a digital rectal exam identifies any abnormalities or areas of concern.

To perform a prostate ultrasound, a slender probe is gently inserted into the rectum. This probe emits sound waves that generate images of the prostate gland. This method, known as transrectal ultrasound (TRUS), provides detailed visual information about the prostate’s structure and can help identify suspicious areas that may require further investigation.

Prostate MRI: Advanced Imaging for Detailed Assessment

Magnetic resonance imaging (MRI) of the prostate is an advanced imaging modality that uses magnetic fields and radio waves to produce detailed images of the prostate gland and surrounding tissues. Prostate MRI is frequently used to investigate suspicious areas within the prostate that could potentially be cancerous.

MRI images offer valuable insights that can guide clinical decision-making, such as whether a prostate biopsy is necessary to obtain tissue samples for further analysis. Furthermore, if a biopsy is indicated, MRI images can aid in biopsy planning, allowing for targeted sampling of concerning regions identified on the MRI.

During a prostate MRI, you will lie on a table that slides into the MRI machine, which is typically a large, tube-shaped magnet. The magnetic field interacts with hydrogen atoms in your body, in conjunction with radio waves, to generate cross-sectional images of the prostate.

Several specialized types of MRI are used in prostate cancer diagnosis:

• Contrast-enhanced MRI: This technique involves injecting a contrast dye into a vein in your arm before the MRI scan. The contrast dye enhances the clarity of the images, making it easier to visualize and differentiate tissues.
• MRI with endorectal coil: This method utilizes an endorectal coil, a thin wire inserted into the rectum, to obtain higher-resolution images of the prostate. The endorectal coil improves image quality by enhancing the signal received by the MRI machine.
• Multiparametric MRI (mpMRI): Multiparametric MRI is a sophisticated technique that provides comprehensive information about prostate tissue characteristics. mpMRI can help distinguish between healthy prostate tissue and cancerous tissue, improving diagnostic accuracy and risk stratification.

Prostate Biopsy: Confirming the Diagnosis

Transrectal Biopsy of the Prostate

Alt text: Illustration of a Transrectal Prostate Biopsy procedure, definitive diagnosis for prostate cancer.

A prostate biopsy is the definitive procedure for diagnosing prostate cancer. It involves extracting a small tissue sample from the prostate gland for microscopic examination in a laboratory. This is the only method to definitively confirm the presence of cancer cells in the prostate.

Prostate biopsies are typically performed using a needle to collect tissue samples. The needle can be inserted either through the skin (perineal biopsy) or through the rectum (transrectal biopsy) to reach the prostate. The choice of biopsy technique depends on individual factors and the healthcare team’s preference.

Common types of prostate biopsy procedures include:

• Transrectal Prostate Biopsy (TRUS biopsy): This is the most frequently performed type of prostate biopsy. During a TRUS biopsy, a thin probe is inserted into the rectum, which generates ultrasound images of the prostate. This probe also guides a biopsy needle through the rectal wall and into the prostate to collect tissue samples from various locations within the gland.
• Perineal Prostate Biopsy: In a perineal prostate biopsy, the needle is inserted through the perineum, the skin between the scrotum and anus, to access the prostate. This approach is less common than transrectal biopsy. Imaging guidance, often ultrasound, is used to direct the needle and obtain tissue samples from different areas of the prostate.

The collected prostate tissue samples are sent to a pathology lab where pathologists analyze them under a microscope to determine if cancer cells are present.

Prostate biopsy carries certain risks, including bleeding, blood in the urine (hematuria), and blood in the semen (hematospermia). Less frequently, it can cause urinary difficulties or infection. Side effects may vary depending on the biopsy type. It is essential to discuss potential risks and recovery expectations with your healthcare team.

Gleason Score and Grade Group: Assessing Cancer Aggressiveness

The Gleason score and grade group are crucial components of prostate cancer diagnosis, providing information about the aggressiveness or growth rate of the cancer. Cancer grade reflects how quickly cancer cells are likely to grow and spread.

Pathologists, specialized doctors who examine tissue samples, determine the grade by analyzing prostate cancer cells obtained during a biopsy. If the cancer cells closely resemble normal, healthy prostate cells, the cancer is considered low-grade, indicating slow growth. Conversely, if the cancer cells appear significantly abnormal and differ markedly from healthy cells, it is classified as high-grade, suggesting more rapid growth.

Prostate cancer grades range from 1 to 5, with grade 1 being the least aggressive (very low grade) and grade 5 being the most aggressive (very high grade). To calculate the Gleason score, pathologists assess multiple biopsy samples, identify the predominant grade and the second most prevalent grade, and sum these two grades.

Gleason scores range from 2 to 10. Scores of 5 or lower are not typically considered indicative of cancer. Gleason scores from 6 to 10 are classified as cancerous. A Gleason score of 6 suggests a slow-growing cancer, while a score of 10 indicates a rapidly growing cancer.

Prostate cancer grade is also reported using grade groups, which provide another way to express cancer aggressiveness. The grade groups are as follows:

• Grade group 1: Gleason score 6 or less.
• Grade group 2: Gleason score 7 (most common grade 3, second most common grade 4).
• Grade group 3: Gleason score 7 (most common grade 4, second most common grade 3).
• Grade group 4: Gleason score 8.
• Grade group 5: Gleason score 9 or 10.

The grade group, along with other factors, is used by your healthcare team to determine the cancer stage and guide treatment planning.

Prostate Cancer Biomarker Tests: Personalized Risk Assessment

Prostate cancer biomarker tests analyze specific substances or markers in the body, particularly in cancer cells, to gain further insights into the cancer’s characteristics and behavior. These tests provide valuable information for personalized risk assessment and treatment decisions.

Biomarker tests in prostate cancer are utilized in several clinical scenarios:

• Determining the need for biopsy: Some biomarker tests analyze blood and urine samples to detect signals associated with prostate cancer cells. These tests can help assess the likelihood of finding cancer on a prostate biopsy, aiding in decisions about whether biopsy is warranted.
• Risk stratification in early prostate cancer: Certain biomarker tests evaluate cancer cells to determine the risk of the cancer spreading beyond the prostate. If initial tests are inconclusive, these biomarker tests can refine risk assessment, helping guide decisions about immediate treatment versus active surveillance (monitoring the cancer closely).
• Treatment guidance in advanced prostate cancer: For prostate cancer that has metastasized (spread to other parts of the body), biomarker tests can identify specific characteristics of the cancer cells. This information can help predict the likelihood of response to certain treatments, guiding treatment selection. These tests may involve analyzing cells from biopsies of metastatic sites or circulating tumor cells in blood samples.

Biomarker testing in prostate cancer is a rapidly evolving field, and not everyone requires these tests. Healthcare professionals are continually refining the appropriate use of biomarker tests in clinical practice.

Imaging Tests for Prostate Cancer Spread: Detecting Metastasis

Imaging tests play a crucial role in determining if prostate cancer has spread beyond the prostate gland to other parts of the body, a condition known as metastasis. These tests can detect cancer spread to lymph nodes, bones, or other organs.

While most men with prostate cancer have localized disease confined to the prostate, imaging for metastasis may be necessary in certain cases, particularly for higher-risk cancers. Discuss with your healthcare team whether imaging tests to assess for cancer spread are recommended for your specific situation.

When prostate cancer spreads, it is termed metastatic, stage 4, or advanced prostate cancer. Imaging tests used to detect metastasis include:

• Bone Scan: A bone scan is a nuclear medicine imaging technique that uses radioactive tracers to visualize bone metabolism. Increased tracer uptake in bones may indicate areas of bone metastasis.
• Computerized Tomography (CT) Scan: CT scans use X-rays to create detailed cross-sectional images of the body. CT scans can detect prostate cancer spread to lymph nodes and other organs.
• Magnetic Resonance Imaging (MRI): MRI, as described previously, can also be used to detect prostate cancer spread beyond the prostate, including to lymph nodes and soft tissues.
• Positron Emission Tomography (PET) Scan: PET scans are nuclear medicine imaging tests that utilize radioactive tracers to detect metabolically active tissues, such as cancer cells. PET scans can identify prostate cancer metastasis in various parts of the body.
• Prostate-Specific Membrane Antigen (PSMA) PET Scan: PSMA PET scans are a specialized type of PET scan that uses a tracer targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. PSMA PET scans are particularly sensitive for detecting prostate cancer metastasis, including in lymph nodes and bones.

Prostate Cancer Stages: Defining the Extent of Disease

Prostate cancer staging is a process that determines the extent and spread of the cancer. The stage is assigned based on the results of diagnostic tests and procedures and is a critical factor in treatment planning and prognosis.

Prostate cancer staging considers several factors:

• Tumor extent within the prostate: How much of the prostate gland is affected by cancer.
• Extracapsular extension: Whether the cancer has grown beyond the prostate capsule into surrounding tissues, such as the seminal vesicles, bladder, or rectum.
• Lymph node involvement: Whether the cancer has spread to regional lymph nodes.
• Distant metastasis: Whether the cancer has spread to distant sites, such as bones or other organs.
• PSA level: The level of prostate-specific antigen in the blood.
• Grade group: The Gleason grade group, reflecting cancer aggressiveness.

Prostate cancer stages range from 1 to 4, with lower stages indicating less advanced, localized disease and higher stages indicating more advanced, metastatic disease. Stage 1 prostate cancer is the least advanced, while stage 4 is the most advanced.

Prostate cancer stages are further categorized into substages, such as stage 2A, 2B, 2C, 3A, 3B, 3C, 4A, and 4B, to provide more granular detail about the extent of the cancer. The specific stage is a crucial determinant of prognosis and treatment options.

Prostate Cancer Prognosis and Survival Rates

Prostate cancer prognosis refers to the predicted course and outcome of the disease. Prognosis is influenced by various factors, including cancer stage, grade group, PSA level, age, overall health, and treatment response.

While prostate cancer stage provides a general indication of prognosis, it is not a definitive predictor of an individual’s future. Personalized prognosis assessment requires considering all relevant factors in consultation with your healthcare team.

Prostate cancer survival rates are statistical measures that indicate the percentage of patients living for a specified period, typically five years, after diagnosis. These statistics are based on large population studies and provide general trends but do not predict individual outcomes.

For localized prostate cancer confined to the prostate, the five-year survival rate is nearly 100%. As the cancer spreads beyond the prostate, survival rates generally decrease. For metastatic prostate cancer that has spread to distant sites, the five-year survival rate is approximately 37%.

It is important to note that survival statistics are based on data collected over several years and may not reflect recent advancements in prostate cancer treatment. Prostate cancer death rates have been declining, and survival rates have been improving due to earlier diagnosis and treatment advancements.

Care at Mayo Clinic

Our caring team of Mayo Clinic experts can help you with your prostate cancer-related health concerns Start Here

More Information

Treatment

Prostate cancer diagnosis is a complex process that involves a series of tests and procedures to accurately detect and characterize the disease. Understanding each step of the diagnostic journey empowers you to engage in informed discussions with your healthcare team and make well-considered decisions about your care. Early diagnosis and appropriate management are crucial for improving outcomes and quality of life for men with prostate cancer.

Request an appointment

Symptoms & causes
Doctors & departments

Feb. 20, 2025

Print

Prostate Cancer Discussions

Can anyone share their experience with Pluvicto? 131 Replies Wed, Mar 26, 2025

chevron-right

Stage 4 prostate cancer treatment options 141 Replies Tue, Mar 25, 2025

chevron-right

What is the average age of the gentlemen on here? 475 Replies Mon, Mar 24, 2025

chevron-right

See more discussions

1. DeVita VT Jr, et al., eds. Cancer of the prostate. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Sept. 24, 2024.
2. Prostate cancer treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq. Accessed Sept. 24, 2024.
3. Prostate cancer early detection. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1460. Accessed Sept. 24, 2024.
4. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed Sept. 26, 2024.
5. Partin AW, et al., eds. Campbell-Walsh-Wein Urology. 12th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
6. Taplin M, et al. Clinical presentation and diagnosis of prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
7. Hematuria (blood in the urine). National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/urologic-diseases/hematuria-blood-urine. Accessed Oct. 7, 2024.
8. Niederhuber JE, et al., eds. Prostate cancer. In: Abeloff’s Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
9. Sartor AO. Risk factors for prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
10. Sartor AO. Chemoprevention strategies in prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
11. Prostate cancer screening (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq. Accessed Sept. 24, 2024.
12. AskMayoExpert. Prostate cancer: Screening (adult). Mayo Clinic; 2023.
13. Fowler GC, et al., eds. Prostate and seminal vesicle ultrasonography and biopsy. In: Pfenninger and Fowler’s Procedures for Primary Care. 4th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Oct. 16, 2024.
14. Prostate MRI. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/mr_prostate. Accessed Oct. 17, 2024.
15. Yang XJ. Interpretation of prostate biopsy. https://www.uptodate.com/contents/search. Accessed Oct. 16, 2024.
16. Biomarker testing for cancer treatment. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment. Accessed Nov. 24, 2024.
17. Genomic diagnostic testing for prostate cancer. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/genomic-diagnostic-testing-for-prostate-cancer. Accessed Nov. 24, 2024.
18. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Sept. 24, 2024.
19. Richie JP. Localized prostate cancer: Risk stratification and choice of initial treatment. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
20. Taplin M, et al. Initial staging and evaluation of males with newly diagnosed prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
21. American College of Surgeons. Prostate. In: AJCC Cancer Staging System. American College of Surgeons; 2023. https://online.statref.com. Accessed Aug. 1, 2024.
22. Population-based cancer survival statistics overview. National Cancer Institute. https://surveillance.cancer.gov/survival. Accessed Oct. 17, 2024.
23. Tepper JE, et al., eds. Prostate cancer. In: Gunderson & Tepper’s Clinical Radiation Oncology. 5th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
24. Pisters LL, et al. Cryotherapy and other ablative techniques for the initial treatment of prostate cancer. https://www.uptodate.com/contents/search. Accessed Nov. 24, 2024.
25. Murad V, et al. MR-guided focused ultrasound focal therapy for prostate cancer. Magnetic Resonance Imaging Clinics of North America. 2024; doi:10.1016/j.mric.2024.04.001.
26. Abida W, et al. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. https://www.uptodate.com/contents/search. Accessed Nov. 23, 2024.
27. Gulley J. Immunotherapy for castration-resistant prostate cancer. https://www.uptodate.com/contents/search. Accessed Nov. 23, 2024.
28. Immune checkpoint inhibitors. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. Accessed Nov. 23, 2024.
29. Dawson NA, et al. Overview of treatment for castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed Nov. 24, 2024.
30. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Sept. 24, 2024.
31. Thompson RH, et al. Radical prostatectomy for octogenarians: How old is too old? The Journal of Urology. 2006; doi:10.1016/j.urology.2006.05.031.
32. Choline C-11 injection (prescribing information). Mayo Clinic PET Radiochemistry Facility; 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed Nov. 24, 2024.
33. Woodrum DA, et al. Targeted prostate biopsy and MR-guided therapy for prostate cancer. Abdominal Radiology. 2016; doi:10.1007/s00261-016-0681-3.
34. Agarwal DK, et al. Initial experience with da Vinci single-port robot-assisted radical prostatectomies. European Urology. 2020; doi:10.1016/j.eururo.2019.04.001.
35. Gettman MT, et al. Current status of robotics in urologic laparoscopy. European Urology. 2003; doi:10.1016/S0302-2838(02)00579-1.
36. Krambeck AE, et al. Radical prostatectomy for prostatic adenocarcinoma: A matched comparison of open retropubic and robot-assisted techniques. BJU International. 2008; doi:10.1111/j.1464-410X.2008.08012.x.
37. What are radiopharmaceuticals? International Atomic Energy Agency. https://www.iaea.org/newscenter/news/what-are-radiopharmaceuticals. Accessed Nov. 24, 2024.